Microwave Ablation for Inoperable Stage I Non–Small Cell Lung Cancer in Patients Aged ≥70 Years: A Prospective, Single-Center Study

Abstract

PurposeTo evaluate the safety and survival outcomes of computed tomography–guided microwave ablation (MWA) for medically inoperable Stage I non–small cell lung cancer (NSCLC) in patients aged ≥70 years. Materials and MethodsThis study was a prospective, single-arm, single-center clinical trial. The MWA clinical trial enrolled patients aged ≥70 years with medically inoperable Stage I NSCLC from January 2021 to October 2021. All patients received biopsy and MWA synchronously with the coaxial technique. The primary endpoints were 1-year overall survival (OS) and progression-free survival (PFS). The secondary endpoint was adverse events. ResultsA total of 103 patients were enrolled. Ninety-seven patients were eligible and analyzed. The median age was 75 years (range, 70–91 years). The median diameter of tumors was 16 mm (range, 6–33 mm). Adenocarcinoma (87.6%) was the most common histologic finding. With a median follow-up of 16.0 months, the 1-year OS and PFS rates were 99.0% and 93.7%, respectively. There were no procedure-related deaths in any patient within 30 days after MWA. Most of the adverse events were minor. ConclusionMWA is an effective and safe treatment for patients aged ≥70 years with medically inoperable Stage I NSCLC.